These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 16956836)

  • 1. Limited effects on JAK2 mutational status after pegylated interferon alpha-2b therapy in polycythemia vera and essential thrombocythemia.
    Samuelsson J; Mutschler M; Birgegård G; Gram-Hansen P; Björkholm M; Pahl HL
    Haematologica; 2006 Sep; 91(9):1281-2. PubMed ID: 16956836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha.
    Stauffer Larsen T; Iversen KF; Hansen E; Mathiasen AB; Marcher C; Frederiksen M; Larsen H; Helleberg I; Riley CH; Bjerrum OW; Rønnov-Jessen D; Møller MB; de Stricker K; Vestergaard H; Hasselbalch HC
    Leuk Res; 2013 Sep; 37(9):1041-5. PubMed ID: 23827351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases.
    Melikyan AL; Subortseva IN; Gilyazitdinova EA; Koloshejnova TI; Pustovaya EI; Egorova EK; Kovrigina AM; Sudarikov AB; Abdullaev AO; Lomaia EG; Siordiya NT; Zaritskey AY; Savchenko VG
    Ter Arkh; 2018 Aug; 90(7):23-29. PubMed ID: 30701919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A gain-of-function mutation of JAK2 in myeloproliferative disorders.
    Kralovics R; Passamonti F; Buser AS; Teo SS; Tiedt R; Passweg JR; Tichelli A; Cazzola M; Skoda RC
    N Engl J Med; 2005 Apr; 352(17):1779-90. PubMed ID: 15858187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New molecular markers within the chronic myeloproliferative disorders. II: the JAK2 mutation].
    Larsen TS; Pallisgaard N; Christensen JH; Gram-Hansen P; Kerndrup GB; Møller MB; Hasselbalch HC
    Ugeskr Laeger; 2006 Sep; 168(39):3299-303. PubMed ID: 17032592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation.
    Huang BT; Zeng QC; Zhao WH; Li BS; Chen RL
    Leuk Res; 2014 Oct; 38(10):1177-83. PubMed ID: 25069759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.
    Quintás-Cardama A; Kantarjian H; Manshouri T; Luthra R; Estrov Z; Pierce S; Richie MA; Borthakur G; Konopleva M; Cortes J; Verstovsek S
    J Clin Oncol; 2009 Nov; 27(32):5418-24. PubMed ID: 19826111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a.
    Kiladjian JJ; Cassinat B; Turlure P; Cambier N; Roussel M; Bellucci S; Menot ML; Massonnet G; Dutel JL; Ghomari K; Rousselot P; Grange MJ; Chait Y; Vainchenker W; Parquet N; Abdelkader-Aljassem L; Bernard JF; Rain JD; Chevret S; Chomienne C; Fenaux P
    Blood; 2006 Sep; 108(6):2037-40. PubMed ID: 16709929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
    Kiladjian JJ; Rain JD; Bernard JF; Briere J; Chomienne C; Fenaux P
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):417-21. PubMed ID: 16810617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case 15-2006: the Budd-Chiari syndrome and V617F mutation in JAK2.
    Spivak JL; Moliterno AR; Silver RT
    N Engl J Med; 2006 Aug; 355(7):737; author reply 738. PubMed ID: 16914715
    [No Abstract]   [Full Text] [Related]  

  • 12. Essential thrombocythemias without V617F JAK2 mutation are clonal hematopoietic stem cell disorders.
    Kiladjian JJ; Elkassar N; Cassinat B; Hetet G; Giraudier S; Balitrand N; Conejero C; Briere J; Fenaux P; Chomienne C; Grandchamp B
    Leukemia; 2006 Jun; 20(6):1181-3. PubMed ID: 16598303
    [No Abstract]   [Full Text] [Related]  

  • 13. JAKing up hematopoietic proliferation.
    Shannon K; Van Etten RA
    Cancer Cell; 2005 Apr; 7(4):291-3. PubMed ID: 15837617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation.
    Hexner E; Roboz G; Hoffman R; Luger S; Mascarenhas J; Carroll M; Clementi R; Bensen-Kennedy D; Moliterno A
    Br J Haematol; 2014 Jan; 164(1):83-93. PubMed ID: 24903629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a.
    Quintás-Cardama A; Abdel-Wahab O; Manshouri T; Kilpivaara O; Cortes J; Roupie AL; Zhang SJ; Harris D; Estrov Z; Kantarjian H; Levine RL; Verstovsek S
    Blood; 2013 Aug; 122(6):893-901. PubMed ID: 23782935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial.
    Gowin K; Jain T; Kosiorek H; Tibes R; Camoriano J; Palmer J; Mesa R
    Leuk Res; 2017 Mar; 54():73-77. PubMed ID: 28113109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera.
    Larsen TS; Bjerrum OW; Pallisgaard N; Andersen MT; Møller MB; Hasselbalch HC
    Ann Hematol; 2008 Oct; 87(10):847-50. PubMed ID: 18481066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
    Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
    Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S; Michiels JJ
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
    Zhan H; Spivak JL
    Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.